Fig. 7

miRNA agomir treatment counteracts various AD pathologies in APP/PS1 mice. a Phosphorylated tau (antibody: AT8) levels are reduced 5 weeks after the completion of agomir treatment in 10–11-MO APP/PS1 mice. Representative images from the hippocampus are shown (left panel). Scale bar, 100 μm. Yellow circles indicate regions of AT8 positivity. Insets: high-magnification images of the representative AT8-positive plaques in each group. Scale bar, 20 μm. The area of AT8 reactivity and number of AT8 plaques per area were quantified within the hippocampus (right panel). Data are presented as mean ± SEM, n = four mice each group. b Agomir treatment reduces activated microglia 5 weeks after the completion of agomir treatment in the hippocampus of 10–11-MO APP/PS1 mice globally. Representative images from the hippocampus are shown. Scale bar, 20 μm. The area fraction positive for Iba1 was quantified within the hippocampus. n = four mice each group. Data are presented as mean ± SEM. c Agomir treatment reduces astrogliosis 5 weeks after the completion of agomir treatment in the hippocampus of 10–11-MO APP/PS1 mice. Representative images from the hippocampus are shown. Scale bar, 20 μm. High-magnification images of GFAP-positive hypertrophic glial cells are shown on the right. Scale bars, 10 μm. The average perikaryon area of glial cells and the percentage of the area of GFAP⁺ astrocytes were quantified within the hippocampus. Data are presented as mean ± SEM, n = four mice each group. d Representative images of synaptophysin expression 5 weeks after the completion of agomir treatment in the DG of 10–11-MO APP/PS1 mice (left panel). Scale bar, 20 µm. The quantification of the area fraction positive for synaptophysin within the DG is shown on the right. Data are presented as mean ± SEM, n = three mice each group. For (a-d), data were analyzed with one-way ANOVA